Olorofim plus standard care for advanced Valley fever
Part of Infections clinical trials.
This study tests a new antifungal medicine called olorofim, combined with standard care, for people with Valley fever that has spread beyond the lungs and hasn't improved with usual treatments. The goal is to see if it helps control the infection better than standard care alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and weigh at least 40 kg (about 88 lbs).
- Your coccidioidomycosis (Valley fever) has spread beyond your lungs and is getting worse or has not responded to treatment.
- You have already tried at least two different azole antifungal medications (like fluconazole or itraconazole), with or without an IV medicine called amphotericin B.
- You are not pregnant or breastfeeding, and you do not have severe liver problems or a history of allergic reactions to the study drug.
- Your symptoms are not solely from permanent damage (for example, from a stroke), and you are not currently taking certain other antifungal medications.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new antifungal treatment for people with certain fungal infections (Valley fever, blastomycosis, histoplasmosis) who have not done well on or can't take their current medicine. The goal is to find a better way to control the infection when the first treatment fails or causes problems.
This study looks at why “Valley fever” is difficult to treat or has spread beyond the lungs, and how a person’s genetics may be involved. You may be asked for blood or other samples for genetic testing and for storing samples for future research.
This trial tests a new drug called olorofim for people recently diagnosed with coccidioidomycosis (Valley fever) meningitis, a serious fungal infection of the brain lining. It aims to see if the drug is safe and effective as an early treatment.
This study tests occidiofungin, a new antifungal medication inserted into the vagina twice a week to prevent recurring yeast infections (vulvovaginal candidiasis). The goal is to see if this treatment can stop yeast infections from coming back.
This study tests a new antifungal drug (EL219) compared to two standard treatments (liposomal amphotericin B or voriconazole) for people with weakened immune systems who have a suspected or confirmed mold infection. The goal is to see if the new drug works as well or better at treating the infection.
This study tests a medicine called isavuconazole, which is used to treat serious fungal infections. It aims to see if it is safe and works well in very sick patients in the intensive care unit (ICU).
Hear when a new Coccidioidomycosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.